UPDATE 1-FDA staff question utility, trials of Novo Nordisk diabetes drug

May 20 (Reuters) - A preliminary review by the U.S. Food and

Drug Administration of Novo Nordisk A/S's experimental

diabetes drug, IDegLira, questioned the interpretability of the

study findings and practical utility of the treatment, according

to a review posted on the agency's website on Friday.

Read more